DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

被引：0

作者：

Board, Ruth E. ^{[1
]}

Knight, Lucy ^{[2
]}

Greystoke, Alastair ^{[1
]}

Blackhall, Fiona H. ^{[3
]}

Hughes, Andrew ^{[4
]}

Dive, Caroline ^{[5
]}

Ranson, Malcolm ^{[6
]}

机构：

[1] Paterson Inst Canc Res, Clin & Expt Pharmacol, Wilmslow Rd, Manchester M20 4BX, Lancs, England

[2] AstraZeneca, Discovery Med, Macclesfield SK10 4TG, Cheshire, England

[3] Christie Hosp NHS Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England

[4] AstraZeneca, Discovery Med, Macclesfield SK10 4TG, Cheshire, England

[5] Paterson Inst Canc Res, Clin & Expt Pharmacol, Manchester M20 4BX, Lancs, England

[6] Christie Hosp NHS Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England

来源：

BIOMARKER INSIGHTS | 2007年 / 2卷

关键词：

DNA methylation; biomarker; circulating tumour DNA; MSP; MethyLight;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Free circulating DNA, which is thought to be derived from the primary tumour, can be detected in the blood of patients with cancer. Detection of genetic and epigenetic alteration in this tumour DNA offers a potential source of development of prognostic and predictive biomarkers for cancer. One such change is DNA methylation of the promotor region of tumour suppressor genes. This causes down regulation of tumour suppressor gene expression, a frequent event in carcinogenesis. Hypermethylation of the promotor region of a number of genes has been detected in many tumour types and more recently these changes have been detected in circulating tumour DNA. This review will summarise the literature detailing DNA methylation in circulating tumour DNA and discuss some of the current controversies and technical challenges facing its use as a potential biomarker for cancer.

引用

页码：307 / 319

页数：13

共 50 条

[1] Circulating tumour DNA as a cancer biomarker
Duffy, Michael J.
[J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2019, 56 (01) : 42 - 48
[2] DNA methylation in circulating free DNA as a new biomarker for pancreatic cancer
Shinjo, Keiko
Ohka, Fumiharu
Katsushima, Keisuke
Hatanaka, Akira
Ichimura, Norihisa
Juan, Zhao
Yamao, Kenji
Kondo, Yutaka
[J]. CANCER RESEARCH, 2015, 75
[3] Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Naidoo, Mahendra
Piercey, Oliver
Tie, Jeanne
[J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (12)
[4] Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Mahendra Naidoo
Oliver Piercey
Jeanne Tie
[J]. Current Oncology Reports, 2021, 23
[5] Circulating tumour DNA, a promising biomarker for the management of colorectal cancer
Khakoo, Shelize
Georgiou, Alexandros
Gerlinger, Marco
Cunningham, David
Starling, Naureen
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 122 : 72 - 82
[6] Circulating tumour DNA as a therapeutic biomarker for radiotherapy
Bratman, S.
[J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S59 - S60
[7] Circulating-tumour DNA methylation of HAND1 gene: a promising biomarker in early detection of colorectal cancer
Shavali, Mehrdad
Moradi, Arash
Tahmaseb, Mohammad
Mohammadian, Kamal
Ganji, Shahla Mohammad
[J]. BMC MEDICAL GENOMICS, 2024, 17 (01)
[8] Potential of circulating tumour DNA as a biomarker in liquid biopsy
Dimitrov, Dimitar
Ivanov, Hristo
Miteva-Marcheva, Nelly
Stoyanova, Vili
[J]. BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2023, 37 (01)
[9] DNA methylation, a biomarker for colorectal cancer
Jubb, AM
Quirke, P
Oates, AJ
[J]. EPIGENETICS IN CANCER PREVENTION: EARLY DETECTION AND RISK ASSESSMENT, 2003, 983 : 251 - 267
[10] DNA methylation age as a biomarker for cancer
Lau, Chung-Ho E.
Robinson, Oliver
[J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (11) : 2652 - 2663

← 1 2 3 4 5 →